Skip to main content

Table 1 Associations of HDAC-1 and −2 expression with clinicopathological parameters in 70 pancreatic adenocarcinoma patients

From: Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

Clinicopathological characteristics HDAC-1 expression HDAC-2 expression
Low (%) High (%) p-value Low (%) High (%) p-value
N = 70 42 (60.0) 28 (40.0)   35 (50.0) 35 (50.0)  
Age (mean ± SD;ys)    0.4880    0.8082
  ≤66.77 ± 8.94 yrs 16 (22.9) 13 (18.6)   14 (20.0) 15 (21.4)  
  >66.77 ± 8.94 yrs 26 (37.1) 15 (21.4)   21 (30.0) 20 (28.6)  
Gender    0.4191    0.6207
  Male 28 (40.0) 16 (22.9)   23 (32.9) 21 (30.0)  
  Female 14 (20.0) 12 (17.1)   12 (17.1) 14 (20.0)  
Histopathological grade    1.0000    0.4945
  I + II 36 (51.4) 24 (34.3)   29 (41.4) 31 (44.3)  
I  II 6 (8.6) 4 (5.7)   6 (8.6) 4 (5.7)  
pT    0.1544    0.2046
  T1 + T2 5 (7.1) 7 (10.0)   4 (5.7) 8 (11.4)  
  T3 + T4 37 (52.9) 21 (30.0)   31 (44.3) 27 (38.6)  
pN    0.0632    0.2312
  0 16 (22.9) 17 (24.3)   19 (27.1) 14 (20.0)  
  1 26 (37.1) 11 (15.7)   16 (22.9) 21 (30.0)  
pM    0.5282    1.0000
  0 39 (55.7) 27 (38.6)   33 (47.1) 33 (47.1)  
  1 3 (4.3) 1 (1.4)   2 (2.9) 2 (2.9)  
pStage    0.1127    0.2320
  I + II 31 (44.3) 25 (35.7)   26 (37.1) 30 (42.9)  
  III + IV 11 (15.7) 3 (4.3)   9 (12.9) 5 (7.1)  
Ki-protein statement    0.0238    0.4703
  ≤ median value 28 (40.0) 11 (15.7)   21 (30.0) 18 (15.7)  
  > median value 14 (20.0) 17 (24.3)   14 (20.0) 17 (24.3)